Judge Nixes Eli Lilly's Axiron Patents In Win For Generics

Law360, New York (August 23, 2016, 9:40 PM EDT) -- A federal judge on Monday largely shut down Eli Lilly & Co.'s patent suit aiming to block generic versions of its testosterone drug Axiron, ruling that three of the four accused generics makers either did not infringe the company's patents or proved them to be invalid.

Judge Sarah Evans Barker of the Southern District of Indiana issued a 214-page opinion following a nine-day bench trial held in June and July, and held that generic versions of the drug planned by Perrigo Co., Actavis Laboratories UT Inc., and Lupin Pharmaceuticals Inc. do not infringe.

The judge found that a fourth defendant, Amneal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!